Worth reading
54Recurring
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.This transaction
Reallocation of Business Functions Following the Closure of the Kobe Research InstituteDate of board resolution13 May 2026
Consideration and expenses
Amount of extraordinary income (loss)References a separate disclosure regarding the recognition of an extraordinary loss (amount and quarter of recognition: Not disclosed in this document)
Impact on Business Performance
The impact of this matter on results is already reflected in the separate disclosure issued today regarding the full-year consolidated earnings forecast and other matters.
Procedures and assumptions
Management structure after acquisitionThe Kobe Research Institute will be closed as originally planned, and the company will consider establishing a flexible operating structure for the genomics business, including the use of external facilities on Kobe Port Island. The large-animal pharmacology business will continue to be consolidated at the Iwata Research Institute as previously planned.
| Item | Details |
|---|---|
| Transaction name | Reallocation of Business Functions Following the Closure of the Kobe Research Institute |
| Amount of extraordinary income (loss) | References a separate disclosure regarding the recognition of an extraordinary loss (amount and quarter of recognition: Not disclosed in this document) |
| Impact on Business Performance | The impact of this matter on results is already reflected in the separate disclosure issued today regarding the full-year consolidated earnings forecast and other matters. |
| Date of board resolution | 13 May 2026 |
| Management structure after acquisition | The Kobe Research Institute will be closed as originally planned, and the company will consider establishing a flexible operating structure for the genomics business, including the use of external facilities on Kobe Port Island. The large-animal pharmacology business will continue to be consolidated at the Iwata Research Institute as previously planned. |
Items this document does not state (27)
Counterparty nameName of the Subject CompanyBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountContract DateExecution Date / Effective DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company determined that consolidating the operations in Kurume might not maximize business value in terms of securing personnel with advanced expertise, ensuring the transfer of expertise and development capabilities, and maintaining and ensuring the continuity of the business foundation.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.